Read by QxMD icon Read


Michèle Voegeli, Stephanie Rondeau, Simona Berardi Vilei, Erika Lerch, Luciano Wannesson, Thomas Pabst, Jochen Rentschler, Mario Bargetzi, Lorenz Jost, Nicolas Ketterer, Angelika Bischof Delaloye, Michele Ghielmini
Standard conditioning regimens for autologous stem cell transplantation (ASCT) are often not tolerated by elderly patients, on one hand. Single high-dose melphalan, on the other hand, has been shown to be safe and active as a pretransplant preparative regimen in elderly patients. Y(90) -Ibritumomab tiuxetan (Y(90) -IT) is well tolerated and feasible in the transplantation setting. We therefore investigated the combination of high-dose melphalan and Y(90) -IT as a conditioning regimen for patients ≥65 years of age...
September 28, 2016: Hematological Oncology
C Tien, R Yedavalli
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
P Ioannides, Y A Abuodeh, W Jin, S E Hoffe, J M Frakes, R Kim, J Choi, G El-Hadda, B Biebel, B Kis, J Sweeney, M Friedman, N Kothari, D Anaya, K Latifi
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
Bin Cai, Michael B Altman, Jose Garcia-Ramirez, Jason LaBrash, S Murty Goddu, Sasa Mutic, Parag J Parikh, Jeffrey R Olsen, Nael Saad, Jacqueline E Zoberi
PURPOSE: To develop a safe and robust workflow for yttrium-90 (Y-90) radioembolization procedures in a multidisciplinary team environment. METHODS AND MATERIALS: A generalized Define-Measure-Analyze-Improve-Control (DMAIC)-based approach to process improvement was applied to a Y-90 radioembolization workflow. In the first DMAIC cycle, events with the Y-90 workflow were defined and analyzed. To improve the workflow, a web-based interactive electronic white board (EWB) system was adopted as the central communication platform and information processing hub...
September 8, 2016: Brachytherapy
Parul Thakral, Suhas Singla, Atul Vashist, Madhav P Yadav, Santosh K Gupta, Jaya S Tyagi, Atul Sharma, Chandra S Bal, EmptyYN Y Snehlata, Arun Malhotra
BACKGROUND AND OBJECTIVES: The aim of the study is to evaluate the therapeutic efficacy and safety of Yttrium- 90 radiolabelled chimeric anti CD20 antibody-Rituximab in the treatment of patients with relapsed/ refractory B cell Non-Hodgkins Lymphoma (NHL). METHODS: Twenty patients with relapsed/refractory CD20+ NHL in progressive state were included in the study. These patients had undergone a median of 2 (range 2-5) prior standard chemotherapy ± immunotherapy regimens...
2016: Current Radiopharmaceuticals
Belkis Erbas, Murat Tuncel
Theranostics labeled with Y-90 or Lu-177 are highly efficient therapeutic approaches for the systemic treatment of various cancers including neuroendocrine tumors and prostate cancer. Peptide receptor radionuclide therapy (PRRT) has been used for many years for metastatic or inoperable neuroendocrine tumors. However, renal and hematopoietic toxicities are the major limitations for this therapeutic approach. Kidneys have been considered as the "critical organ" because of the predominant glomerular filtration, tubular reabsorption by the proximal tubules, and interstitial retention of the tracers...
September 2016: Seminars in Nuclear Medicine
Katherine Y Fan, Aaron T Wild, Vivek G Halappa, Rachit Kumar, Susannah Ellsworth, Mark Ziegler, Tanu Garg, Lauren M Rosati, Zheng Su, Amy Hacker-Prietz, Timothy M Pawlik, David P Cosgrove, Kelvin K Hong, Ihab R Kamel, Jean-Francois Geschwind, Joseph M Herman
OBJECTIVE: Yttrium-90 (Y-90) radioembolization is an emerging treatment option for unresectable neuroendocrine liver metastases (NELM). However, the data regarding this treatment are currently limited. This study evaluates the efficacy and tolerability of Y-90 radioembolization and identifies prognostic factors for radiographic response and survival. METHODS AND MATERIALS: Thirty-eight patients underwent Y-90 radioembolization for NELM at our institution between April 2004 and February 2012...
September 2016: Contemporary Clinical Trials
Jonathan I Gear, Craig Cummings, Allison J Craig, Antigoni Divoli, Clive D C Long, Michael Tapner, Glenn D Flux
BACKGROUND: The use of selective internal radiation therapy (SIRT) is rapidly increasing, and the need for quantification and dosimetry is becoming more widespread to facilitate treatment planning and verification. The aim of this project was to develop an anthropomorphic phantom that can be used as a validation tool for post-SIRT imaging and its application to dosimetry. METHOD: The phantom design was based on anatomical data obtained from a T1-weighted volume-interpolated breath-hold examination (VIBE) on a Siemens Aera 1...
December 2016: EJNMMI Physics
Mootaz Eldib, Niels Oesingmann, David D Faul, Lale Kostakoglu, Karin Knešaurek, Zahi A Fayad
PURPOSE: Positron emission tomography (PET) imaging of yttrium-90 in the liver post radioembolization has been shown useful for personalized dosimetry calculations and evaluation of extrahepatic deposition. The purpose of this study was to quantify the benefits of several MR-based data correction approaches offered by using a combined PET/MR system to improve Y-90 PET imaging. In particular, the feasibility of motion and partial volume corrections were investigated in a controlled phantom study...
August 2016: Medical Physics
Joanna Zalewska, Małgorzata Węgierska, Tacjana Barczyńska, Marzena Waszczak, Paweł Żuchowski, Sławomir Jeka
OBJECTIVES: Hypertrophic and exudative synovitis of the knee is one of the earliest symptoms in rheumatic diseases. In the case of pharmacotherapy failure, other methods which directly remove the inflamed synovial membrane are used - synovectomies. Radiosynovectomy (RSV) is the radiopharmaceutical application of colloidal solution to joint cavities. In this study, the authors assessed the efficacy of knee radiosynovectomy with yttrium-90 (Y-90) in several groups of patients divided into certain rheumatic diseases...
2016: Reumatologia
Mary Ellen Koran, Andrew J Lipnik, Jennifer C Baker, Filip Banovac, Reed A Omary, Daniel B Brown
PURPOSE: We tested the hypothesis that establishing a dedicated interventional oncology (IO) clinical service line would increase clinic visits and procedural volumes at a single quaternary care academic medical center. METHODS: Two time periods were defined: July 2012 to June 2013 (pre-IO clinic) and July 2013 to June 2014 (first year of dedicated IO service). Staff was recruited, and clinic space was provided in the institution's comprehensive cancer center. Clinic visits and procedure numbers were documented using the institution's electronic medical record and billing forms...
September 2016: Journal of the American College of Radiology: JACR
Smit Singla, Charles M LeVea, Venkata K Pokuri, Kristopher M Attwood, Michael M Wach, Garin M Tomaszewski, Boris Kuvshinoff, Renuka Iyer
BACKGROUND: Neuroendocrine tumors (NETs) metastatic to the liver are treated with transarterial radioembolization (TARE) using yttrium-90 (Y-90) microspheres or transarterial chemoembolization (TACE). However the criteria for patient selection are not well defined. We sought to determine if Ki67 score could help select patients for one therapy over the other in the management of hepatic neuroendocrine metastases. METHODS: Single institution analysis of patients treated with Y-90 or TACE between 2001 and 2014...
June 2016: Journal of Gastrointestinal Oncology
Martin Šefl, Ioanna Kyriakou, Dimitris Emfietzoglou
PURPOSE: To study theoretically the impact on cell survival of the radionuclide uptake rate inside tumor cells for a single administration of a radiopharmaceutical. METHODS: The instantaneous-uptake model of O'Donoghue ["The impact of tumor cell proliferation in radioimmunotherapy," Cancer 73, 974-980 (1994)] for a proliferating cell population irradiated by an exponentially decreasing dose-rate is here extended to allow for the monoexponential uptake of the radiopharmaceutical by the targeted cells...
June 2016: Medical Physics
Thomas W Barber, Martin H Cherk, Anne Powell, Kenneth S K Yap, Baki Billah, Victor Kalff
BACKGROUND: It is unclear how to predict which patients will respond to Y-90 radiosynoviorthesis. The aim of this study is to correlate clinical outcomes following Y-90 radiosynoviorthesis with bremsstrahlung and Y-90 PET/CT imaging findings. METHODS: Fifty-one joints underwent bremsstrahlung planar and Y-90 PET/CT imaging following Y-90 radiosynoviorthesis. The Y-90 distribution pattern on bremsstrahlung planar imaging was classified as diffuse or non-diffuse and compared with the intra or extra-articular location of activity on Y-90 PET/CT...
December 2016: EJNMMI Research
Murat Fani Bozkurt, Bilge Volkan Salanci, Ömer Uğur
Intra-arterial radionuclide therapies serve essentially as internal radiation treatment options for both primary and metastatic liver tumors, which imply delivering implantable radioactive microspheres into branches of hepatic arteries that feed liver tumors to provide a high dose of targeted radiation to tumor tissue, while sparing the healthy liver tissue from hazardous effects of radiation. The principle of this therapeutic option depends on the unique preferential arterial supply of malignant liver tumors in contrast with mostly portal venous supply of normal hepatocytes as well as excess amount of arterial neovascularization in the tumor bed...
July 2016: Seminars in Nuclear Medicine
Samuel Durán Agüero, Eloina Fernández Godoy, Elena Carrasco Piña
Introducción: la hiperglicemia es la característica principal de la diabetes (DM). La restricción de CHO en la dieta presenta el mayor efecto en la disminución de los niveles de glucosa en sangre tanto en DM 1 y 2.Objetivo: asociar la ingesta de macro y micronutrientes con el control metabólico de pacientes con diabetes tipo 2.Material y métodos: se entrevistó a 714 pacientes diabéticos tipo 2 de ambos sexos, entre 27 y 90 años, en centros de salud familiar de Santiago de Chile. Se les aplicó una encuesta alimentaria y una evaluación antropométrica...
2016: Nutrición Hospitalaria: Organo Oficial de la Sociedad Española de Nutrición Parenteral y Enteral
Aaron K T Tong, Yung Hsiang Kao, Chow Wei Too, Kenneth F W Chin, David C E Ng, Pierce K H Chow
In recent years, yttrium-90 ((90)Y) microsphere radioembolization has been establishing itself as a safe and efficacious treatment for both primary and metastatic liver cancers. This extends to both first-line therapies as well as in the salvage setting. In addition, radioembolization appears efficacious for patients with portal vein thrombosis, which is currently a contraindication for surgery, transplantation and transarterial chemoembolization. This article reviews the efficacy and expanding use of (90)Y microsphere radioembolization with an added emphasis on recent advances in personalized dosimetry and interventional radiology techniques...
June 2016: British Journal of Radiology
V I Anisimkin, C Caliendo, E Verona
The sensing behavior to liquids for Acoustic Plate Modes (APMs) propagating along 64°Y, 90°X LiNbO3 plate was investigated vs. two electric boundary conditions. The changes in the APMs phase velocity and attenuation were measured upon exposure to different liquids wetting one of the surfaces of the plate, either free or electrically shorted by a thin conductive Al layer. The experimental data confirm that the presence of a metallic layer covering one of the plate surfaces affects the viscosity and temperature sensitivity of the device...
May 2016: Ultrasonics
Seza A Gulec
At present, the systemic treatment of unresectable colorectal cancer liver metastases involves oxaliplatin and irinotecan-based chemotherapy regimens combined with targeted therapies such as bevacizumab (Avastin) and cetuximab (Erbitux). Radiation therapy, traditionally, is not considered a viable treatment modality owing to its unacceptably high hepatic toxicity, and still steering traditional wisdom or dogma that chemoradiation cannot be an oncological strategy for a stage IV disease. Selective internal radiation treatment with yttrium-90 (Y-90) radiomicrospheres has emerged as an effective liver-directed therapy with a favorable therapeutic ratio...
March 2016: Seminars in Nuclear Medicine
Peter Kletting, Thomas Kull, Christian Maaß, Noeen Malik, Markus Luster, Ambros J Beer, Gerhard Glatting
UNLABELLED: In peptide receptor radionuclide therapy with (90)Y-labeled DOTATATE, the kidney absorbed dose limits the maximum amount of total activity that can be safely administered in many patients. A higher tumor-to-kidney absorbed dose ratio might be achieved by optimizing the amount of injected peptide and activity, as recent studies have shown different degrees of receptor saturation for normal tissue and tumor. The aim of this work was to develop and implement a modeling method for treatment planning to determine the optimal combination of peptide amount and pertaining therapeutic activity for each patient...
April 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"